Phase 2 Study of BA058 (Abaloparatide) Transdermal Delivery in Postmenopausal Women With Osteoporosis

NCT01674621 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

250

Enrollment

INDUSTRY

Sponsor class

Conditions

Post Menopausal Osteoporosis

Interventions

DRUG: Abaloparatide Transdermal (50 mcg)
DRUG: Abaloparatide Transdermal (100 mcg)
DRUG: Abaloparatide Transdermal (150 mcg)
DRUG: Abaloparatide Injection (80 mcg)
DRUG: Abaloparatide Placebo

Sponsor

Radius Health, Inc.

Collaborators

[object Object]